DE69223206T2 - Anti-menschliche Milchfettglobule humanisierte Antikörper - Google Patents
Anti-menschliche Milchfettglobule humanisierte AntikörperInfo
- Publication number
- DE69223206T2 DE69223206T2 DE69223206T DE69223206T DE69223206T2 DE 69223206 T2 DE69223206 T2 DE 69223206T2 DE 69223206 T DE69223206 T DE 69223206T DE 69223206 T DE69223206 T DE 69223206T DE 69223206 T2 DE69223206 T2 DE 69223206T2
- Authority
- DE
- Germany
- Prior art keywords
- hams
- derived
- milk fat
- human milk
- humanized antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB919120467A GB9120467D0 (en) | 1991-09-26 | 1991-09-26 | Anti-hmfg antibodies and process for their production |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69223206D1 DE69223206D1 (de) | 1998-01-02 |
DE69223206T2 true DE69223206T2 (de) | 1998-06-25 |
Family
ID=10701993
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69223206T Expired - Lifetime DE69223206T2 (de) | 1991-09-26 | 1992-09-24 | Anti-menschliche Milchfettglobule humanisierte Antikörper |
DE69232991T Expired - Lifetime DE69232991T2 (de) | 1991-09-26 | 1992-09-24 | Anti-menschliche Milchfettglobule humanisierte Antikörper und Verfahren zu ihrer Herstellung |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69232991T Expired - Lifetime DE69232991T2 (de) | 1991-09-26 | 1992-09-24 | Anti-menschliche Milchfettglobule humanisierte Antikörper und Verfahren zu ihrer Herstellung |
Country Status (13)
Country | Link |
---|---|
US (1) | US6506881B1 (de) |
EP (2) | EP0534742B1 (de) |
JP (1) | JP3498957B2 (de) |
AT (2) | ATE160362T1 (de) |
AU (1) | AU666868B2 (de) |
CA (1) | CA2095926C (de) |
DE (2) | DE69223206T2 (de) |
DK (1) | DK0781845T3 (de) |
ES (1) | ES2108732T3 (de) |
GB (1) | GB9120467D0 (de) |
IL (1) | IL103269A (de) |
NZ (1) | NZ244468A (de) |
WO (1) | WO1993006231A1 (de) |
Families Citing this family (103)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
AU5615594A (en) * | 1992-11-13 | 1994-06-08 | Cancer Research Fund Of Contra Costa | Polypeptides with specificity for neoplasias, kit, and diagnostic, vaccination, and therapeutic methods |
US6281335B1 (en) * | 1993-10-08 | 2001-08-28 | Coulter Corporation | Hybridoma and anti-KC-4 humanized monoclonal antibody |
WO1994011509A2 (en) * | 1992-11-16 | 1994-05-26 | Cancer Research Fund Of Contra Costa | Peptides and anti-sense peptides with broad neoplastic specificity |
US6074642A (en) * | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
US5773001A (en) * | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
PT784684E (pt) * | 1994-09-16 | 2007-11-23 | Cancer Res Fund Of Contra Cost | ''péptidos recontinantes derivados do anticorpo mc3 anti-ba46, métodos para a sua utilização e métodos de hmnanização de péptidos do anticorpo'' |
US5712374A (en) * | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
US7361336B1 (en) * | 1997-09-18 | 2008-04-22 | Ivan Bergstein | Methods of cancer therapy targeted against a cancer stem line |
GB9812545D0 (en) | 1998-06-10 | 1998-08-05 | Celltech Therapeutics Ltd | Biological products |
US20040009535A1 (en) | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
IL143266A0 (en) | 1998-11-27 | 2002-04-21 | Darwin Discovery Ltd | Transforming growth factor-beta binding proteins and pharmaceutical compositions for increasing bone mineral content utilizing the same |
GB2360771A (en) * | 2000-03-28 | 2001-10-03 | Antisoma Res Ltd | Compounds for targeting |
WO2001074905A1 (en) * | 2000-04-03 | 2001-10-11 | Antisoma Research Limited | Compounds for targeting |
AU2001248840B2 (en) | 2000-04-21 | 2005-06-09 | Fuso Pharmaceutical Industries, Ltd. | Novel collectins |
GB0013810D0 (en) | 2000-06-06 | 2000-07-26 | Celltech Chiroscience Ltd | Biological products |
WO2002062850A2 (en) * | 2001-02-02 | 2002-08-15 | Millennium Pharmaceuticals, Inc. | Hybrid antibodies and uses thereof |
US6441163B1 (en) * | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
GB0124317D0 (en) | 2001-10-10 | 2001-11-28 | Celltech R&D Ltd | Biological products |
EP1534753B1 (de) | 2002-05-28 | 2011-08-03 | UCB Pharma, S.A. | Peg-positionsisomer von einem antikorper gegen tnfalpha (cdp870) |
GB0303337D0 (en) | 2003-02-13 | 2003-03-19 | Celltech R&D Ltd | Biological products |
CN101356194B (zh) | 2005-12-09 | 2013-06-12 | Ucb医药有限公司 | 对人il-6具有特异性的抗体分子 |
AU2007227218A1 (en) | 2006-03-22 | 2007-09-27 | Viral Logic Systems Technology Corp. | Methods for identifying polypeptide targets and uses thereof for treating immunological diseases |
US8377448B2 (en) | 2006-05-15 | 2013-02-19 | The Board Of Trustees Of The Leland Standford Junior University | CD47 related compositions and methods for treating immunological diseases and disorders |
WO2008030538A2 (en) * | 2006-09-07 | 2008-03-13 | Stemline Therapeutics, Inc. | Cancer stem cell-targeted cancer therapy |
GB0620729D0 (en) | 2006-10-18 | 2006-11-29 | Ucb Sa | Biological products |
US8092804B2 (en) | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
GB0807413D0 (en) | 2008-04-23 | 2008-05-28 | Ucb Pharma Sa | Biological products |
EP2283862B1 (de) * | 2008-06-02 | 2018-08-08 | The University of Tokyo | Kombinationstherapie mit anti-mfg-e8 antikörper zur behandlung von krebs |
EP2145901B1 (de) * | 2008-07-18 | 2012-11-14 | Technische Universität Braunschweig | Rekombinante anti-MUC1-Antikörper |
MA33122B1 (fr) | 2009-02-17 | 2012-03-01 | Ucb Pharma Sa | Molecules d'anticorps ayant une specificite pour ox40 humain |
GB0904214D0 (en) | 2009-03-11 | 2009-04-22 | Ucb Pharma Sa | Biological products |
ES2667258T3 (es) | 2009-09-10 | 2018-05-10 | Ucb Biopharma Sprl | Anticuerpos multivalentes |
GB0920127D0 (en) | 2009-11-17 | 2009-12-30 | Ucb Pharma Sa | Antibodies |
GB0920324D0 (en) | 2009-11-19 | 2010-01-06 | Ucb Pharma Sa | Antibodies |
GB201000467D0 (en) | 2010-01-12 | 2010-02-24 | Ucb Pharma Sa | Antibodies |
TW201134488A (en) | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
CA2791930A1 (en) | 2010-03-11 | 2011-09-15 | Kerry Louise Tyson | Pd-1 antibody |
WO2011117653A1 (en) | 2010-03-25 | 2011-09-29 | Ucb Pharma S.A. | Disulfide stabilized dvd-lg molecules |
GB201005064D0 (en) | 2010-03-25 | 2010-05-12 | Ucb Pharma Sa | Biological products |
GB201012599D0 (en) | 2010-07-27 | 2010-09-08 | Ucb Pharma Sa | Process for purifying proteins |
GB201014033D0 (en) | 2010-08-20 | 2010-10-06 | Ucb Pharma Sa | Biological products |
ME02734B (de) | 2011-01-14 | 2017-10-20 | Ucb Biopharma Sprl | Antikörpermodule zur bindung an il-17a und il-17f |
CN103958544B (zh) | 2011-09-16 | 2018-04-24 | Ucb医药有限公司 | 针对艰难梭菌的主要外毒素TcdA和TcdB的中和抗体 |
UA112203C2 (uk) | 2011-11-11 | 2016-08-10 | Юсб Фарма С.А. | Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини |
GB201203051D0 (en) | 2012-02-22 | 2012-04-04 | Ucb Pharma Sa | Biological products |
GB201203071D0 (en) | 2012-02-22 | 2012-04-04 | Ucb Pharma Sa | Biological products |
GB201208370D0 (en) | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Antibodies |
GB201223276D0 (en) | 2012-12-21 | 2013-02-06 | Ucb Pharma Sa | Antibodies and methods of producing same |
GB201315487D0 (en) | 2013-08-30 | 2013-10-16 | Ucb Pharma Sa | Antibodies |
GB201320066D0 (en) | 2013-11-13 | 2013-12-25 | Ucb Pharma Sa | Biological products |
GB201409558D0 (en) | 2014-05-29 | 2014-07-16 | Ucb Biopharma Sprl | Method |
GB201411320D0 (en) | 2014-06-25 | 2014-08-06 | Ucb Biopharma Sprl | Antibody construct |
GB201412658D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
GB201412659D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
GB201506870D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
GB201506869D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
JP2018515082A (ja) | 2015-04-30 | 2018-06-14 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 代謝障害を処置するための抗ap2抗体及び抗原結合剤 |
GB201508180D0 (en) | 2015-05-13 | 2015-06-24 | Ucb Biopharma Sprl | Antibodies |
EA039951B1 (ru) | 2015-05-27 | 2022-03-31 | Юсб Биофарма Спрл | Ингибитор активности csf-1r, предназначенный для лечения или профилактики эпилепсии или болезни паркинсона, и фармацевтическая композиция на его основе |
NZ738058A (en) | 2015-07-06 | 2021-07-30 | UCB Biopharma SRL | Tau-binding antibodies |
GB201601073D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies |
GB201601077D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibody molecule |
GB201601075D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies molecules |
KR20180067676A (ko) | 2015-10-27 | 2018-06-20 | 유씨비 바이오파마 에스피알엘 | 항-il-17a/f 항체를 사용한 치료 방법 |
GB201521389D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Method |
GB201521382D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
GB201521393D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
GB201521391D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
GB201521383D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl And Ucb Celltech | Method |
GB201522394D0 (en) | 2015-12-18 | 2016-02-03 | Ucb Biopharma Sprl | Antibodies |
US11534496B2 (en) | 2016-06-07 | 2022-12-27 | The Brigham And Women's Hospital, Inc. | Compositions and methods relating to T peripheral helper cells in autoantibody-associated conditions |
GB201610198D0 (en) | 2016-06-10 | 2016-07-27 | Ucb Biopharma Sprl | Anti-ige antibodies |
JP2020500834A (ja) | 2016-08-26 | 2020-01-16 | エージェンシー フォー サイエンス,テクノロジー アンド リサーチ | マクロファージ刺激タンパク質受容体(又はRON(Recepteur d′Origine Nantais))抗体及びその使用 |
GB201616596D0 (en) | 2016-09-29 | 2016-11-16 | Nascient Limited | Epitope and antibodies |
GB201621635D0 (en) | 2016-12-19 | 2017-02-01 | Ucb Biopharma Sprl | Crystal structure |
WO2018183366A1 (en) | 2017-03-28 | 2018-10-04 | Syndax Pharmaceuticals, Inc. | Combination therapies of csf-1r or csf-1 antibodies and a t-cell engaging therapy |
KR20240042244A (ko) | 2017-05-19 | 2024-04-01 | 신닥스 파마슈티컬스, 인크. | 조합 요법 |
GB201802486D0 (en) | 2018-02-15 | 2018-04-04 | Ucb Biopharma Sprl | Methods |
MA53903A (fr) | 2018-10-16 | 2021-08-25 | UCB Biopharma SRL | Méthode de traitement de la myasthénie grave |
AU2020247175A1 (en) | 2019-03-26 | 2021-10-14 | Aslan Pharmaceuticals Pte Ltd | Treatment employing anti-IL-13R antibody or binding fragment thereof |
GB201919062D0 (en) | 2019-12-20 | 2020-02-05 | Ucb Biopharma Sprl | Antibody |
GB201919061D0 (en) | 2019-12-20 | 2020-02-05 | Ucb Biopharma Sprl | Multi-specific antibody |
GB201919058D0 (en) | 2019-12-20 | 2020-02-05 | Ucb Biopharma Sprl | Multi-specific antibodies |
GB202001447D0 (en) | 2020-02-03 | 2020-03-18 | Ucb Biopharma Sprl | Antibodies |
IL301859A (en) | 2020-10-15 | 2023-06-01 | UCB Biopharma SRL | Binding molecules for CD45 multimerization |
US20230406924A1 (en) | 2020-11-02 | 2023-12-21 | UCB Biopharma SRL | Use of anti-trem1 neutralizing antibodies for the treatment of motor neuron neurodegenerative disorders |
AR124250A1 (es) | 2020-12-07 | 2023-03-01 | UCB Biopharma SRL | Anticuerpos |
PE20231953A1 (es) | 2020-12-07 | 2023-12-06 | UCB Biopharma SRL | Anticuerpos multiespecificos y combinaciones de anticuerpos |
WO2022186772A1 (en) | 2021-03-01 | 2022-09-09 | Aslan Pharmaceuticals Pte Ltd | TREATMENT OF ATOPIC DERMATITIS EMPLOYING ANTI-IL-13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF |
WO2022186773A1 (en) | 2021-03-01 | 2022-09-09 | Aslan Pharmaceuticals Pte Ltd | TREATMENT OF ATOPIC DERMATITIS EMPLOYING ANTI-IL-13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF IN AN ALLERGIC POPULATION |
EP4067381A1 (de) | 2021-04-01 | 2022-10-05 | Julius-Maximilians-Universität Würzburg | Neue tnfr2-bindende moleküle |
AR125732A1 (es) | 2021-05-03 | 2023-08-09 | UCB Biopharma SRL | Anticuerpos anti-trem1 |
GB202111905D0 (en) | 2021-08-19 | 2021-10-06 | UCB Biopharma SRL | Antibodies |
WO2023048650A1 (en) | 2021-09-27 | 2023-03-30 | Aslan Pharmaceuticals Pte Ltd | TREATMENT OF PRURITIS EMPLOYING ANTI-IL13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF |
WO2023048651A1 (en) | 2021-09-27 | 2023-03-30 | Aslan Pharmaceuticals Pte Ltd | Method for treatment of moderate to severe atoptic dematitis |
GB202115122D0 (en) | 2021-10-21 | 2021-12-08 | Dualyx Nv | Binding molecules targeting IL-2 receptor |
WO2023075702A1 (en) | 2021-10-29 | 2023-05-04 | Aslan Pharmaceuticals Pte Ltd | Anti-il-13r antibody formulation |
WO2023140780A1 (en) | 2022-01-24 | 2023-07-27 | Aslan Pharmaceuticals Pte Ltd. | Method of treating inflammatory disease |
TW202337905A (zh) | 2022-02-23 | 2023-10-01 | 新加坡商亞獅康私人有限公司 | 抗il13r抗體之糖基化形式 |
GB202210679D0 (en) | 2022-07-21 | 2022-09-07 | Dualyx Nv | Binding molecules targeting il-12rb2 |
WO2024043837A1 (en) | 2022-08-26 | 2024-02-29 | Aslan Pharmaceuticals Pte Ltd | High concentration anti-il13r antibody formulation |
WO2024054157A1 (en) | 2022-09-06 | 2024-03-14 | Aslan Pharmaceuticals Pte Ltd | Treatment for sleep loss or sleep disturbance in patients with dermatitis |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2584293B1 (fr) * | 1985-07-04 | 1989-03-17 | Ire Celltarg Sa | Anticorps utiles comme agents de pilotage et conjugues les incorporant |
GB8607679D0 (en) * | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
IL162181A (en) * | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
IL93733A (en) * | 1989-04-14 | 1996-01-19 | American Cyanamid Co | History of Dissolved Drug Sulphides Antibacterial and Antibacterial, Prepared from Compounds Containing Methyl-Thriteo Groups and Their Target Form |
GB8928874D0 (en) * | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
-
1991
- 1991-09-26 GB GB919120467A patent/GB9120467D0/en active Pending
-
1992
- 1992-09-24 DE DE69223206T patent/DE69223206T2/de not_active Expired - Lifetime
- 1992-09-24 JP JP50593493A patent/JP3498957B2/ja not_active Expired - Lifetime
- 1992-09-24 ES ES92308680T patent/ES2108732T3/es not_active Expired - Lifetime
- 1992-09-24 DE DE69232991T patent/DE69232991T2/de not_active Expired - Lifetime
- 1992-09-24 AT AT92308680T patent/ATE160362T1/de not_active IP Right Cessation
- 1992-09-24 AT AT97200482T patent/ATE236251T1/de not_active IP Right Cessation
- 1992-09-24 WO PCT/GB1992/001759 patent/WO1993006231A1/en active Application Filing
- 1992-09-24 EP EP92308680A patent/EP0534742B1/de not_active Expired - Lifetime
- 1992-09-24 NZ NZ244468A patent/NZ244468A/en unknown
- 1992-09-24 EP EP97200482A patent/EP0781845B1/de not_active Expired - Lifetime
- 1992-09-24 DK DK97200482T patent/DK0781845T3/da active
- 1992-09-24 CA CA002095926A patent/CA2095926C/en not_active Expired - Lifetime
- 1992-09-24 IL IL103269A patent/IL103269A/en not_active IP Right Cessation
- 1992-09-24 AU AU25983/92A patent/AU666868B2/en not_active Expired
-
1995
- 1995-05-25 US US08/450,809 patent/US6506881B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JPH06505399A (ja) | 1994-06-23 |
AU2598392A (en) | 1993-04-27 |
DE69223206D1 (de) | 1998-01-02 |
CA2095926A1 (en) | 1993-03-27 |
NZ244468A (en) | 1994-11-25 |
ATE236251T1 (de) | 2003-04-15 |
DK0781845T3 (da) | 2003-06-16 |
IL103269A (en) | 1998-01-04 |
EP0534742B1 (de) | 1997-11-19 |
DE69232991T2 (de) | 2004-01-15 |
EP0781845A2 (de) | 1997-07-02 |
ATE160362T1 (de) | 1997-12-15 |
GB9120467D0 (en) | 1991-11-06 |
AU666868B2 (en) | 1996-02-29 |
JP3498957B2 (ja) | 2004-02-23 |
CA2095926C (en) | 2002-07-16 |
EP0534742A1 (de) | 1993-03-31 |
EP0781845A3 (de) | 1997-07-09 |
ES2108732T3 (es) | 1998-01-01 |
WO1993006231A1 (en) | 1993-04-01 |
DE69232991D1 (de) | 2003-05-08 |
IL103269A0 (en) | 1993-02-21 |
EP0781845B1 (de) | 2003-04-02 |
US6506881B1 (en) | 2003-01-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69223206D1 (de) | Anti-menschliche Milchfettglobule humanisierte Antikörper | |
ATE137534T1 (de) | Cdr-gepfropfte anti-cea-antikörper und ihre herstellung | |
Co et al. | Genetically engineered deglycosylation of the variable domain increases the affinity of an anti-CD33 monoclonal antibody | |
EP0347433B1 (de) | Rekombinant-antikörper | |
MX9201016A (es) | Anticuerpos monoclonales humanizados y quimericos | |
GB2246781A (en) | CD3 specific recombinant antibody | |
FI973120A (fi) | Ihmisen gp39:n eri epitoopeille spesifisiä monoklonaalisia vasta-aineita ja menetelmiä niiden käyttämiseksi diagnosoinnissa ja terapiassa | |
DE69636748D1 (de) | Bispezifischer antikörper zur effektiven behandlung von b-zell lymphomen und zellinien | |
BR9106232A (pt) | Molecula de anticorpo recombinante,cadeia pesada humanizada,cadeia leve,sequencia de dna,vetor de clonagem,celula hospedeira,processos para produzir um anticorpo e um produto de anticorpo,e uma composicao terapeutica,composicao terapeutica,processo para terapia ou diagnose e processo para o tratamento de homens e animais | |
JPH03501440A (ja) | 免疫反応性ヘテロ鎖抗体 | |
MY145703A (en) | Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumors | |
KR900013986A (ko) | 종양-관련항원에 대한 모노클로날 항체(MAb_s), 이의 제조방법 및 용도 | |
ATE370235T1 (de) | Rekombinantpeptide hergeleitet vom mc3 antikörper gegen ba46, verfahren zu deren verwendung und verfahren zur humanisierung von antikörperpeptiden | |
KR940006602A (ko) | 면역글로불린 이소타입에 대한 재조형 모노클로날 항체 | |
Orlandi et al. | Characterization of a mouse‐human chimeric antibody to a cancer‐associated antigen | |
Kremmer et al. | Murine anti‐mouse T cell monoclonal antibodies elicit anti‐antibodies in mice: intra‐species immunization model for estimating potential patient sensitization against humanized anti‐T cell antibodies | |
HOURANIEH | MONOCLONAL ANTIBODY WITH SPECIFICITY TO HUMAN XL-FIBRIN. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
R071 | Expiry of right |
Ref document number: 534742 Country of ref document: EP |